Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting (NCT07308639)

Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting NCT07308639 Sponsor: Bayer Condition: Retinal Vein Occlusion and Diabetic Macular Oedema

Printed from Voxsanity (voxsanity.com.au) — NCT07308639 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Retinal Vein Occlusion

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with at least one of the following eye conditions between January 1, 2009 and December 31, 2024: wet age-related macular degeneration (nAMD), diabetic macular edema (DME), or a blockage of a blood vessel in the retina (RVO)
If you have wet age-related macular degeneration (nAMD), you must be 50 years old or older
If you have diabetic macular edema (DME), you must be 18 years old or older
If you have a retinal vein blockage (RVO), you must be 18 years old or older
You currently live in Germany and have either public (statutory) or private health insurance

Who may not be able to join:

There are no listed exclusion criteria for this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: (+)1-888-84 22937

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07308639

Sponsor: Bayer

Phase: Not Applicable

Status: Recruiting

Condition: Retinal Vein Occlusion and Diabetic Macular Oedema

Trial contact: (+)1-888-84 22937

More information: https://clinicaltrials.gov/study/NCT07308639

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with at least one of the following eye conditions between January 1, 2009 and December 31, 2024: wet age-related macular degeneration (nAMD), diabetic macular edema (DME), or a blockage of a blood vessel in the retina (RVO)
If you have wet age-related macular degeneration (nAMD), you must be 50 years old or older
If you have diabetic macular edema (DME), you must be 18 years old or older
If you have a retinal vein blockage (RVO), you must be 18 years old or older
You currently live in Germany and have either public (statutory) or private health insurance

Who may not be able to join:

There are no listed exclusion criteria for this trial

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Bayer

Registry

ClinicalTrials.gov

Start date

3 March 2026

Est. completion

31 December 2026

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

incidence of nAMD, DME and RVO of FDZ and FDPG in Germany; prevalence of nAMD, DME and RVO in Germany

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov